Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells

Molecular and Cellular Endocrinology

Volumn 369, Issue 1-2, 2013, Pages 27-34

  Delgado Calle, Jesús ^a   Arozamena, Jana ^a   Pérez López, Javier ^a   Bolado Carrancio, Alfonso ^a   Sañudo, Carolina ^a   Agudo, Gloria ^a   de la Vega, Rosa ^a   Alonso, María A ^b   Rodríguez Rey, José Carlos ^a   Riancho, José A ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

BMPs; DNA methylation; Gene transcription; SOST

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; SCLEROSTIN;

AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA METHYLATION; EPIGENETICS; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; OSTEOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SOST GENE; TRANSCRIPTION REGULATION; UPREGULATION;

AZACITIDINE; BONE MORPHOGENETIC PROTEINS; CELL LINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOPOROTIC FRACTURES; SIGNAL TRANSDUCTION;

EID: 84875026383     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.02.002     Document Type: Article

References (51)

1. Agholme F., Li X., Isaksson H., Ke H.Z., Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J. Bone Miner. Res. 2010, 25:2412-2418.
2. Atkins G.J., Rowe P.S., Lim H.P., Welldon K.J., Ormsby R., Wijenayaka A.R., Zelenchuk L., Evdokiou A., Findlay D.M. Sclerostin is a locally acting regulator of late-osteoblast/pre-osteocyte differentiation and regulates mineralization through a MEPE-ASARM dependent mechanism. J. Bone Miner. Res. 2011, 26:1425-1436.
3. Bonewald L.F. The amazing osteocyte. J. Bone Miner. Res. 2011, 26:229-238.
4. Bonnet N., Standley K.N., Bianchi E.N., Stadelmann V., Foti M., Conway S.J., Ferrari S.L. The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J. Biol. Chem. 2009, 284:35939-35950.
5. Brunetti G., Oranger A., Mori G., Specchia G., Rinaldi E., Curci P., Zallone A., Rizzi R., Grano M., Colucci S. Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann. N. Y. Acad. Sci. 2011, 1237:19-23.
6. Cain C.J., Rueda R., McLelland B., Collette N.M., Loots G.G., Manilay J.O. Absence of sclerostin adversely affects B-cell survival. J. Bone Miner. Res. 2012, 27:1451-1461.
7. Cejka D., Herberth J., Branscum A.J., Fardo D.W., Monier-Faugere M.C., Diarra D., Haas M., Malluche H.H. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin. J. Am. Soc. Nephrol. 2011, 6:877-882.
8. Chen G., Deng C., Li Y.P. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int. J. Biol. Sci. 2012, 8:272-288.
9. Cohen-Kfir E., Artsi H., Levin A., Abramowitz E., Bajayo A., Gurt I., Zhong L., D'Urso A., Toiber D., Mostoslavsky R., Dresner-Pollak R. Sirt1 is a regulator of bone mass and a repressor of SOST encoding for sclerostin: a bone formation inhibitor. Endocrinology 2011, 152:4514-4524.
10. Colucci S., Brunetti G., Oranger A., Mori G., Sardone F., Specchia G., Rinaldi E., Curci P., Liso V., Passeri G., Zallone A., Rizzi R., Grano M. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J. 2011, 1:e27.
11. Dallas S.L., Bonewald L.F. Dynamics of the transition from osteoblast to osteocyte. Ann. N. Y. Acad. Sci. 2010, 1192:437-443.
12. Delgado-Calle J., Arozamena J., Garcia-Renedo R., Garcia-Ibarbia C., Pascual-Carra M.A., Gonzalez-Macias J., Riancho J.A. Osteocyte deficiency in hip fractures. Calcif. Tissue Int. 2011, 89:327-334.
13. Delgado-Calle J., Sanudo C., Sanchez-Verde L., Garcia-Renedo R.J., Arozamena J., Riancho J.A. Epigenetic regulation of alkaline phosphatase in human cells of the osteoblastic lineage. Bone 2011, 49:830-838.
14. Delgado-Calle J., Sanudo C., Bolado A., Fernández A., Arozamena J., Pascual-Carra M.A., Rodriguez-Rey J.C., Fraga M., Bonewald L.F., Riancho J.A. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes. J. Bone Miner. Res. 2012, 27:926-937.
15. Devarajan-Ketha H., Craig T.A., Madden B.J., Robert B.H., Kumar R. The sclerostin-bone protein interactome. Biochem. Biophys. Res. Commun. 2012, 417:830-835.
16. Genetos D.C., Toupadakis C.A., Raheja L.F., Wong A., Papanicolaou S.E., Fyhrie D.P., Loots G.G., Yellowley C.E. Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J. Cell Biochem. 2010, 110:457-467.
17. Gkotzamanidou M., Dimopoulos M.A., Kastritis E., Christoulas D., Moulopoulos L.A., Terpos E. Sclerostin: a possible target for the management of cancer-induced bone disease. Expert. Opin. Ther. Targets 2012, 16:761-769.
18. Huang d.W., Sherman B.T., Tan Q., Kir J., Liu D., Bryant D., Guo Y., Stephens R., Baseler M.W., Lane H.C., Lempicki R.A. DAVID bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucl. Acids Res. 2007, 35:W169-W175.
19. Huang d.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
20. Huang Z., Ren P.G., Ma T., Smith R.L., Goodman S.B. Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability. Cytokine 2010, 51:305-310.
21. Kamiya N., Ye L., Kobayashi T., Lucas D.J., Mochida Y., Yamauchi M., Kronenberg H.M., Feng J.Q., Mishina Y. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J. Bone Miner. Res. 2008, 23:2007-2017.
22. Kamiya N., Ye L., Kobayashi T., Mochida Y., Yamauchi M., Kronenberg H.M., Feng J.Q., Mishina Y. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 2008, 135:3801-3811.
23. Kamiya N., Kobayashi T., Mochida Y., Yu P.B., Yamauchi M., Kronenberg H.M., Mishina Y. Wnt inhibitors Dkk1 and SOST are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J. Bone Miner. Res. 2010, 25:200-210.
24. Leupin O., Kramer I., Collette N.M., Loots G.G., Natt F., Kneissel M., Keller H. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res. 2007, 22:1957-1967.
25. Leupin O., Piters E., Halleux C., Hu S., Kramer I., Morvan F., Bouwmeester T., Schirle M., Bueno-Lozano M., Fuentes F.J., Itin P.H., Boudin E., de Freitas F., Jennes K., Brannetti B., Charara N., Ebersbach H., Geisse S., Lu C.X., Bauer A., Van Hul W., Kneissel M. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J. Biol. Chem. 2011, 286:19489-19500.
26. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., Harris S.E., Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 2005, 280:19883-19887.
27. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., Gao Y., Shalhoub V., Tipton B., Haldankar R., Chen Q., Winters A., Boone T., Geng Z., Niu Q.T., Ke H.Z., Kostenuik P.J., Simonet W.S., Lacey D.L., Paszty C. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 2009, 24:578-588.
28. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., Li Y., Feng G., Gao X., He L. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J. Bone Miner. Res. 2009, 24:1651-1661.
29. Loots G.G., Keller H., Leupin O., Murugesh D., Collette N.M., Genetos D.C. TGF-beta regulates sclerostin expression via the ECR5 enhancer. Bone 2012, 50:663-669.
30. McCullough K.A., Waits C.A., Garimella R., Tague S.E., Sipe J.B., Anderson H.C. Immunohistochemical localization of bone morphogenetic proteins (BMPs) 2, 4, 6, and 7 during induced heterotopic bone formation. J. Orthop. Res. 2007, 25:465-472.
31. Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-Hora M., Feng J.Q., Bonewald L.F., Kodama T., Wutz A., Wagner E.F., Penninger J.M., Takayanagi H. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 2011, 17:1231-1234.
32. Noel D., Gazit D., Bouquet C., Apparailly F., Bony C., Plence P., Millet V., Turgeman G., Perricaudet M., Sany J., Jorgensen C. Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cells. Stem Cells 2004, 22:74-85.
33. O'Brien C.A., Plotkin L.I., Galli C., Goellner J.J., Gortazar A.R., Allen M.R., Robling A.G., Bouxsein M., Schipani E., Turner C.H., Jilka R.L., Weinstein R.S., Manolagas S.C., Bellido T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 2008, 3:e2942.
34. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 2011, 26:19-26.
35. Papanicolaou S.E., Phipps R.J., Fyhrie D.P., Genetos D.C. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology 2009, 46:389-399.
36. Poole K.E., van Bezooijen R.L., Loveridge N., Hamersma H., Papapoulos S.E., Lowik C.W., Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005, 19:1842-1844.
37. Raggatt L.J., Partridge N.C. Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 2010, 285:25103-25108.
38. Riancho J.A., Liu Y., Sainz J., Garcia-Perez M.A., Olmos J.M., Bolado-Carrancio A., Valero C., Perez-Lopez J., Cano A., Yang T., Sanudo C., Deng H.W., Rodriguez-Rey J.C. Nuclear receptor NR5A2 and bone: gene expression and association with bone mineral density. Eur. J. Endocrinol. 2012, 166:69-75.
39. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., Mantila S.M., Gluhak-Heinrich J., Bellido T.M., Harris S.E., Turner C.H. Mechanical stimulation of bone in vivo reduces osteocyte expression of SOST/sclerostin. J. Biol. Chem. 2008, 283:5866-5875.
40. Santos A., Bakker A.D., Willems H.M., Bravenboer N., Bronckers A.L., Klein-Nulend J. Mechanical loading stimulates BMP7, but not BMP2, production by osteocytes. Calcif. Tissue Int. 2011, 89:318-326.
41. Sasaki M., Anast J., Bassett W., Kawakami T., Sakuragi N., Dahiya R. Bisulfite conversion-specific and methylation-specific PCR: a sensitive technique for accurate evaluation of CpG methylation. Biochem. Biophys. Res. Commun. 2003, 309:305-309.
42. Sevetson B., Taylor S., Pan Y. Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J. Biol. Chem. 2004, 279:13849-13858.
43. Sutherland M.K., Geoghegan J.C., Yu C., Turcott E., Skonier J.E., Winkler D.G., Latham J.A. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004, 35:828-835.
44. Sutherland M.K., Geoghegan J.C., Yu C., Winkler D.G., Latham J.A. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004, 35:448-454.
45. ten Dijke P., Krause C., de Gorter D.J., Lowik C.W., van Bezooijen R.L. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J. Bone Joint Surg. Am. 2008, 90(Suppl. 1):31-35.
46. Vaananen H.K., Zhao H., Mulari M., Halleen J.M. The cell biology of osteoclast function. J. Cell Sci. 2000, 113(Pt 3):377-381.
47. Vincent C., Findlay D.M., Welldon K.J., Wijenayaka A.R., Zheng T.S., Haynes D.R., Fazzalari N.L., Evdokiou A., Atkins G.J. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J. Bone Miner. Res. 2009, 24:1434-1449.
48. Wijenayaka A.R., Kogawa M., Lim H.P., Bonewald L.F., Findlay D.M., Atkins G.J. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 2011, 6:e25900.
49. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., Shpektor D., Jonas M., Kovacevich B.R., Staehling-Hampton K., Appleby M., Brunkow M.E., Latham J.A. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003, 22:6267-6276.
50. Yang F., Tang W., So S., de Crombrugghe B., Zhang C. Sclerostin is a direct target of osteoblast-specific transcription factor osterix. Biochem. Biophys. Res. Commun. 2010, 400:684-688.
51. Yu Y.Y., Lieu S., Lu C., Miclau T., Marcucio R.S., Colnot C. Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair. Bone 2010, 46:841-851.